In 1995, Lefebvre et al. reported that SMN1 and SMN2 genes are related to the pathogenesis of SMA [12], and in 2016, nusinersen became the first drug approved for treatment of SMA in the US [15]. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.